HER2-Positive Breast Cancer | Clinical

Early Clinical Activity Observed With TAC01-HER2 in HER2-Positive Solid Tumors

October 20, 2022

TAC01-HER2 elicited encouraging safety and clinical activity in patients with HER2-positive solid tumors with no dose limiting toxicities, cytokine release syndrome, or immune effector cell-associated neurotoxicity observed.

Recommended Approaches to Treatment for Early-Stage HER2+ Breast Cancer

October 13, 2022

During a Targeted Oncology case-based roundtable event, Jennifer M. Matro, MD, discussed the data supporting systemic therapies for treatment of early-stage HER2-positive breast cancer including trastuzumab and pertuzumab.